5 Pharmaceutical Stocks to Buy According to Timothy Lynch’s Stonepine Capital

Page 1 of 5

In this article, we will discuss the 5 pharmaceutical stocks to buy according to Timothy Lynch’s Stonepine Capital based on Q2 2021 holdings of the fund. If you want to read our detailed analysis of Timothy Lynch’s history, investment philosophy, and hedge fund preference, go directly to the 10 Pharmaceutical Stocks to Buy According to Timothy Lynch’s Stonepine Capital.

5. Ovid Therapeutics Inc. (NASDAQ:OVID)

Stonepine Capital’s Stake Value: $7.820 million

Percentage of Stonepine Capital’s 13F Portfolio: 4.08%

Number of Hedge Fund Holders: 15

Ovid Therapeutics Inc. (NASDAQ: OVID) focuses on inventing and developing treatments for individuals who suffer from specific rare neurological conditions such as Angelman syndrome, Fragile X syndrome, Tuberous Sclerosis Complex, and Infantile Spasms. The company was incorporated in 2014 and is placed fifth on the list of 10 pharmaceutical stocks to buy according to Timothy Lynch’s Stonepine Capital.

Page 1 of 5